Compare Stocks: RXRX, CRSP, APGE, and PCVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.84	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
CRSP CRISPR Therapeutics	$53.28 +5.6%	$55.03	$44.12 ▼ $78.00	$5.14B	1.76	1.75 million shs	659,698 shs
PCVX Vaxcyte	$69.72 +7.2%	$59.74	$39.87 ▼ $90.75	$10.39B	1.23	1.57 million shs	1.17 million shs
RXRX Recursion Pharmaceuticals	$4.28 +8.2%	$3.54	$2.77 ▼ $7.18	$2.28B	1.04	19.06 million shs	14.74 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	0.00%	+1.06%	+185.92%
CRSP CRISPR Therapeutics	-3.65%	-9.02%	-7.92%	-5.45%	-34.31%
PCVX Vaxcyte	-2.91%	+15.99%	+7.70%	+11.68%	+59.57%
RXRX Recursion Pharmaceuticals	-7.49%	-2.95%	+14.83%	+10.96%	-35.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.84	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
CRSP CRISPR Therapeutics	$53.28 +5.6%	$55.03	$44.12 ▼ $78.00	$5.14B	1.76	1.75 million shs	659,698 shs
PCVX Vaxcyte	$69.72 +7.2%	$59.74	$39.87 ▼ $90.75	$10.39B	1.23	1.57 million shs	1.17 million shs
RXRX Recursion Pharmaceuticals	$4.28 +8.2%	$3.54	$2.77 ▼ $7.18	$2.28B	1.04	19.06 million shs	14.74 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	0.00%	+1.06%	+185.92%
CRSP CRISPR Therapeutics	-3.65%	-9.02%	-7.92%	-5.45%	-34.31%
PCVX Vaxcyte	-2.91%	+15.99%	+7.70%	+11.68%	+59.57%
RXRX Recursion Pharmaceuticals	-7.49%	-2.95%	+14.83%	+10.96%	-35.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.16	Hold	$126.77	-6.14% Downside
CRSP CRISPR Therapeutics	2.68	Moderate Buy	$67.94	27.51% Upside
PCVX Vaxcyte	2.63	Moderate Buy	$108.60	55.77% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	88.54% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, APGE, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/9/2026	CRSP CRISPR Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/5/2026	PCVX Vaxcyte	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$116.00 ➝ $125.00
10/5/2026	PCVX Vaxcyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$89.00
10/5/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $122.00
10/2/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/28/2026	PCVX Vaxcyte	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$133.00 ➝ $130.00
9/28/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/23/2026	CRSP CRISPR Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
CRSP CRISPR Therapeutics	$11M	468.38	N/A	N/A	$20.17 per share	2.64
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
RXRX Recursion Pharmaceuticals	$74.68M	30.65	N/A	N/A	$2.14 per share	2.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)

Latest RXRX, CRSP, APGE, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	RXRX Recursion Pharmaceuticals	-$0.24	N/A	N/A	N/A	$12.98 million	N/A
11/3/2026	Q3 2026	PCVX Vaxcyte	-$2.1344	N/A	N/A	N/A	$12.50 million	N/A
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
CRSP CRISPR Therapeutics	0.34	17.85	17.85
PCVX Vaxcyte	N/A	5.72	5.72
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CRSP CRISPR Therapeutics	69.20%
PCVX Vaxcyte	96.78%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
CRSP CRISPR Therapeutics	5.20%
PCVX Vaxcyte	3.30%
RXRX Recursion Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
PCVX Vaxcyte	507	148.81 million	143.89 million	Optionable
RXRX Recursion Pharmaceuticals	600	535.34 million	499.74 million	Optionable

RXRX, CRSP, APGE, and PCVX Headlines

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 50,000 Shares

October 9 at 4:38 AM | americanbankingnews.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 25,000 Shares of Stock

October 8 at 6:22 AM | insidertrades.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $125,000.00 in Stock

October 7 at 7:07 PM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 50,000 Shares of Stock

October 7 at 7:07 PM | marketbeat.com

Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

October 7 at 1:21 AM | americanbankingnews.com

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

October 6 at 6:50 PM | zacks.com

Cathie Wood’s ARK Sells Twist Bioscience Shares, Buys Recursion and Intellia

October 6 at 1:29 PM | coincentral.comC

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Falls 4.3% - Here's Why

October 6 at 12:39 PM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Sees Heavy Call Option Buying

October 5, 2026 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% - Here's Why

October 5, 2026 | americanbankingnews.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% - Should You Buy?

October 5, 2026 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) and Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Comparison

October 5, 2026 | americanbankingnews.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of September

October 2, 2026 | msn.com

Reviewing Recursion Pharmaceuticals (NASDAQ:RXRX) & Zealand Pharma A/S (OTCMKTS:ZLDPF)

September 30, 2026 | americanbankingnews.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Climb 4.7% - What's Next?

September 29, 2026 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

September 28, 2026 | zacks.com

Recursion Pharmaceuticals Inc (RXRX)

September 25, 2026 | ru.investing.com

Cours Recursion Pharmaceuticals, Inc.

September 25, 2026 | zonebourse.comZ

Squeeze Watch: 10 Stocks With Over 33% Short Interest

September 25, 2026 | benzinga.com

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

September 24, 2026 | zacks.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 8.8% - Here's What Happened

September 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, APGE, and PCVX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$53.28 +2.84 (+5.64%)

As of 12:12 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Vaxcyte NASDAQ:PCVX

$69.72 +4.71 (+7.25%)

As of 12:12 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.28 +0.33 (+8.23%)

As of 12:12 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, APGE, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, APGE, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, APGE, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, APGE, and PCVX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

CRISPR Therapeutics NASDAQ:CRSP

Vaxcyte NASDAQ:PCVX

Recursion Pharmaceuticals NASDAQ:RXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, APGE, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, APGE, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, APGE, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, APGE, and PCVX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

CRISPR Therapeutics NASDAQ:CRSP

Vaxcyte NASDAQ:PCVX

Recursion Pharmaceuticals NASDAQ:RXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools